Device Trial Radar · NCT03905057
Early Shockwave Therapy for Post-RP ED
Last checked: Nov 20, 2026Latest source record: Apr 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
94
Planned (sponsor's estimate)
Start
Mar 26, 2018
Primary completion
Jun 2021
Study completion Jun 2021
Sponsor
- Lead sponsor
- Dornier MedTech SystemsNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Hospital Universitari de Bellvitge
- First posted
- Apr 5, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Male only, from 50 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot study aims to explore the feasibility, safety and effectiveness of two different extracorporeal shock wave therapy (ESWT) protocols for patients receiving nerve-sparing radical prostatectomy (RP).
Conditions
- Erectile Dysfunction Following Radical Prostatectomy
Interventions
Dornier Aries 2 (with active applicator)Device
Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.
Dornier Aries 2 (with sham applicator)Device
Sham ESWT - No shockwave administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- The difference in average Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF) between the groups at 28-week follow upTime frame: 28-week follow up visit
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.